Aclaris Therapeutics, Inc.

NasdaqGS:ACRS 주식 보고서

시가총액: US$91.9m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aclaris Therapeutics 관리

관리 기준 확인 4/4

Aclaris Therapeutics' CEO는 Neal Walker, Jul2012 에 임명되었습니다 의 임기는 11.92 년입니다. 총 연간 보상은 $ 73.50K, 802.3% 로 구성됩니다. 802.3% 급여 및 -702.3% 보너스(회사 주식 및 옵션 포함). 는 $ 1.47M 가치에 해당하는 회사 주식의 1.82% 직접 소유합니다. 1.47M. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 10.1 년입니다.

주요 정보

Neal Walker

최고 경영자

US$73.5k

총 보상

CEO 급여 비율802.3%
CEO 임기11.9yrs
CEO 소유권1.8%
경영진 평균 재임 기간2yrs
이사회 평균 재임 기간10.1yrs

최근 관리 업데이트

Recent updates

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

May 03
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10
Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08
What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Dec 14
We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?

Aug 25
Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?

Aclaris Therapeutics (ACRS) Investor Presentation - Slideshow

Jun 08

Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation

May 28
Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation

CEO 보상 분석

Neal Walker 의 보수는 Aclaris Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$74kn/a

-US$88m

Sep 30 2023n/an/a

-US$115m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$6mUS$590k

-US$87m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$7mUS$567k

-US$91m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$71m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$2mUS$424k

-US$51m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$3mUS$500k

-US$114m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$4mUS$550k

-US$82m

Sep 30 2018n/an/a

-US$81m

Jun 30 2018n/an/a

-US$79m

Mar 31 2018n/an/a

-US$86m

Dec 31 2017US$810kUS$510k

-US$50m

보상 대 시장: Neal 의 총 보상 ($USD 73.50K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 683.56K ).

보상과 수익: Neal 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Neal Walker (54 yo)

11.9yrs

테뉴어

US$73,500

보상

Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...

리더십 팀

이름위치테뉴어보상소유권
Neal Walker
Co-Founder11.9yrsUS$73.50k1.82%
$ 1.7m
Kevin Balthaser
Chief Financial Officer1.4yrsUS$2.34m0.034%
$ 30.9k
Joseph Monahan
Chief Scientific Officer3.4yrsUS$2.26m0.26%
$ 241.2k
James Loerop
Chief Business Officer2.4yrsUS$2.33m0.048%
$ 43.9k
Matthew Rothman
General Counsel & Corporate Secretary2yrs데이터 없음데이터 없음
Jon Jacobsen
Senior Vice President of Chemistryno data데이터 없음데이터 없음
Steve Tucker
Senior Vice President of Project Leadershipless than a year데이터 없음데이터 없음
Ajay Aggarwal
Senior Vice President of Clinical Developmentless than a year데이터 없음데이터 없음

2.0yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: ACRS 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Neal Walker
Co-Founder11.9yrsUS$73.50k1.82%
$ 1.7m
Vincent Milano
Independent Director4.4yrsUS$180.38k0.018%
$ 16.2k
Mark Bradshaw
Member of Advisory Boardno data데이터 없음데이터 없음
James Leyden
Member of Advisory Boardno data데이터 없음데이터 없음
Klaus Theobald
Member of Advisory Boardno data데이터 없음데이터 없음
Anand Mehra
Independent Director9.8yrsUS$194.38k0.061%
$ 55.9k
Pearl Grimes
Member of Advisory Boardno data데이터 없음데이터 없음
Guy Webster
Member of Advisory Boardno data데이터 없음데이터 없음
Christopher Molineaux
Lead Independent Director10.4yrsUS$206.88k0.075%
$ 68.6k
Kenneth Beer
Member of Advisory Boardno data데이터 없음데이터 없음
Leslie Baumann
Member of Advisory Boardno data데이터 없음데이터 없음
Andrew Ondo
Member of Advisory Boardno data데이터 없음데이터 없음

10.1yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: ACRS 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.1 년).